12:00 AM
 | 
Jul 11, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/8 close
Cepheid Inc. (NASDAQ:CPHD) Goldman Sachs Isaac Ro Downgrade Neutral (from buy) -8% $32.40
Ro downgraded based on Cepheid's strong stock performance. He noted the molecular diagnostic company's stock has risen 40% since he initiated coverage with a Buy rating on Feb. 23. Ro is maintaining his $35 target and his estimates over the 2011-2014 period, which call for compound annual growth of 23% for revenues and 132% for EPS.
Curis Inc. (NASDAQ:CRIS) Roth Capital Partners ...

Read the full 613 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >